Contents

SECTION 1: CLINICAL SPECTRUM

1. **Heart Failure in Women: Decoding the Missing Link** 3
   Harshit Khare, Roopali Khanna
2. **Prevention of Heart Failure: The Chopra–Levy Online Heart Protection Program** 9
   Rick Levy, Lisa Tatum
3. **Salt Intake Thresholds: Ultralow versus Low Sodium Debate** 13
   AK Pancholia
4. **Trivandrum Heart Failure Registry** 18
   Harikrishnan S, Sanjay G, Jeemon P
5. **ACC/AHA/HFSA Guidelines Update in Heart Failure Pharmacotherapy** 23
   Shraddha Ranjan, Manish Bansal, Ravi R Kasliwal, HK Chopra
6. **Clinical Guidelines for HFrEF: AHA, ACC and ESC** 30
   Tapan Sinha, Jayanta Sharma, Mrinal Kanti Das
7. **Noise Pollution, Cardiovascular Disease, and Heart Failure** 40
   Chanchal Pal, HK Chopra

SECTION 2: DRUGS IN HEART FAILURE

Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure

8. **Angiotensin Receptor–Neprilysin Inhibitor and Heart Failure: An Iconic Molecule of Century** 49
   HK Chopra, Chandrashekhar K Ponde, Viveka Kumar, Anu Grover
9. **New ACC/AHA and HFSA Guidelines of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure** 66
   Abhishek, Gurpreet Singh Wander
10. **Top 10 Take-Home Messages from ACC/AHA and HFSA on Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure** 72
    Satyendra Tewari, Ashish Kumar Singh, Ashvanee Kumar Sharma
11. **2023 American College of Cardiology Expert Consensus for Heart Failure with Preserved Ejection Fraction in Clinical Context** 77
    Rajeev Gupta
12. **Differentiation between Heart Failure with Preserved Ejection Fraction and Heart Failure with Reduced Ejection Fraction** 89
    Sanjay Mittal, Aparajita Kumar
13. **Mechanism of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure** 96
    Harsh Wardhan, Ramanand P Sinha, Parth Mashru, Aditya Goyal
14. **Reverse Cardiac Remodeling: Role of Angiotensin Receptor–Neprilysin Inhibitor** 100
    Chandrashekhar K Ponde, Kunal A Patankar
15. **Angiotensin Receptor–Neprilysin Inhibitor Algorithm and Guideline-directed Medical Therapy Management of Heart Failure with Preserved Ejection Fraction** 108
    Mohit D Gupta, Ghazi Muheeb, Girish MP

16. **ARNI Algorithm and GDMT Management of HFrEF** 114
Subhasish Deb, Ranjit Kr Nath

17. **Angiotensin Receptor–Neprilysin Inhibitors in Heart Failure: Outcome Data** 118
Sunil Roy Thottuvelil, Venugopal Krishnan Nair

18. **How Long to Use Angiotensin Receptor–Neprilysin Inhibitor Therapy in Heart Failure: Evidence-based Data** 123
Rupesh Agarwal, Girish MP, Mohit D Gupta

19. **Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibitor in Acute Myocardial Infarction: Current Status** 128
Saumitra Ray, Srina Ray

20. **Angiotensin Receptor–Neprilysin Inhibitor in Postmyocardial Infarction and Heart Failure** 131
Viveka Kumar

21. **Angiotensin Receptor–Neprilysin Inhibitor Postpercutaneous Coronary Intervention in ST-elevation Myocardial Infarction to Prevent Heart Failure** 134
Sameer Gupta, Purshotam Lal, Richa Aggarwal

22. **Angiotensin Receptor–Neprilysin Inhibitor and Cardiac Arrhythmia in Heart Failure** 138
Surendra Chutani, Arun Chutani, Jui Shah

23. **Angiotensin Receptor–Neprilysin Inhibitor in Ischemic Cardiomyopathy: New Dimensions** 141
HK Chopra, Shachi Kalyani, Viveka Kumar

24. **Angiotensin Receptor–Neprilysin Inhibitor from Molecular Structure to Clinical Application in Heart Failure** 146
VK Katyal, Ashima Katyal, Bijender Singh

25. **Angiotensin Receptor–Neprilysin Inhibitor for Doxorubicin-mediated Cardiotoxicity and Heart Failure** 152
Vansh Arora, Raajit Chanana

26. **Renal Safety and Efficacy of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure** 155
Dinesh Khullar, Raghav Khullar, Deepak Kumar Panigrahi

27. **Angiotensin Receptor–Neprilysin Inhibitor: "When, for Whom, and How Long in Heart Failure?"** 162
Brian Pinto, Surendra Poonia

28. **Angiotensin Receptor–Neprilysin Inhibitor and Mineralocorticoid Receptor Antagonist Combination in PARAGON-HF: Odd Couple or Dynamic Duo?** 167
Vaibhav Bandil, Suman Bhandari

29. **Role of the Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter 2 Inhibitor in Women with Heart Failure** 171
Mohan Bhargava, Ankit Kumar, Ashutosh Baheti

30. **Angiotensin Receptor–Neprilysin Inhibitor Improves Sexual Functions and Fibrosis of the Clitoral and Vaginal Tissues in Females with Heart Failure** 180
Deepak K Jumani

31. **Is It Time to Adopt Angiotensin Receptor–Neprilysin Inhibitor Therapy as Standard Care for Management of Hypertension?** 184
Neelesh Pandey, Neeraj Pandit

32. **Role of Angiotensin Receptor Blocker and Neprilysin Inhibitor in Resistant Hypertension** 191
Lokre A, Dayasagar Rao V

33. **Will ARNI Replace ARBs/ACEI in Hypertension to Heart Failure?** 197
Jabir Abdullakutty, Vijin Joseph

34. Role of Angiotensin Receptor–Neprilysin Inhibitor in Septic Cardiomyopathy **201**
SN Pathak, Deeptanshu Jain, Pradeep Jain

35. Role of Angiotensin Receptor–Neprilysin Inhibitor in Takotsubo Cardiomyopathy **205**
Rakesh Varma, Shekhar Kunal, Arvind Dambalkar

36. Role of Angiotensin Receptor–Neprilysin Inhibitor in Dilated Cardiomyopathy **211**
Manbir Singh, Vivudh Pratap Singh

37. Role of Angiotensin Receptor–Neprilysin Inhibitor in Critical Care Patients with Heart Failure **215**
Aashish Jain, Manish Bansal, Yatin Mehta

38. Role of Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients on Ventilator **220**
Surabhi Awasthi, Kapil Dixit, Vikas Yadav, Anshika Chaturvedi Kashyap

39. Role of Angiotensin Receptor–Neprilysin Inhibitors in Heart Failure after Heart Transplant Patients **227**
Shobhit Saurav, Ratna Malika Kumar, Rajneesh Malhotra

40. Role of Angiotensin Receptor–Neprilysin Inhibitors in Patients with Heart Failure on Pacemaker and Arrhythmias **231**
Prashant T Upasani, Sameer Gupta, Purshotam Lal

41. MitraClip in Heart Failure in Patients on Angiotensin Receptor–Neprilysin Inhibitors: When and How? **240**
Ramesh Daggubati, Abdul Subhan Talpur, Mustafa Sajjad Cheema

42. Role of Angiotensin Receptor–Neprilysin Inhibitor in Pulmonary Arterial Hypertension with Heart Failure **246**
Arun K Chopra, Neha Chopra

43. Patiromer in Hyperkalemia in Heart Failure and Chronic Kidney Disease and Angiotensin Receptor–Neprilysin Inhibitor Use **250**
Kaushik Manna, Navanil Biswas, DP Sinha

44. Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure: Pharmacodynamics and Outcome **255**
Anil Pareek, Rujul Desai

Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure

45. New European Society of Cardiology Guidelines of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure **263**
Ashish Kumar Jain, JPS Sawhney, Simran Sawhney

46. Top Ten Trials of Sodium–Glucose Cotransporter 2 Inhibitors **268**
Sanchita Sen, Olivia Mechanic, Christos Mihos, Deepika Misra

47. The Evolving Landscape: Integrating Sodium–Glucose Cotransporter 2 Inhibitors in the Contemporary Management of Heart Failure **274**
Saumitra Ray, HK Chopra, Sanjay Jain, Onkar C Swami

48. The Power and Promise of Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure with Preserved Ejection Fraction **282**
HK Chopra, Anu Grover, Viveka Kumar, Anil Pareek

49. Power and Promise of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Outcome Data **290**
Satyendra Tewari, Ashvanee Kumar Sharma, Ashish Kumar Singh

50. Clinical Outcome Data with Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure **297**
Anil Dhall, Suman Jatain, Mahendra Chouhan, Jasneet Singh

51. Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure **307**
Maitreyee Bhattacharyya, Aditya Kapoor

52. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure **311**
Vinod Mittal

53. Sodium–Glucose Cotransporter 2 Inhibitors in Pulmonary Hypertension in Heart Failure **317**
Bhagwan Mantri, Ritesh Sharma, Tanymol

54. Indication, Contraindication, and Uniqueness of Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure **321**
HK Chopra, Md Inamul Haque, Sunil M Raheja

55. Role of Sodium–Glucose Cotransporter 2 Inhibitor in Dilated Cardiomyopathy with Heart Failure **330**
Saubhik Kanjilal, Arup Dasbiswas

56. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Hypertrophic Obstructive Cardiomyopathy with Heart Failure **337**
Sumit Rakshit, Debabrata Roy

57. Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitor is Important Irrespective of Ejection Fraction **340**
Kajal Ganguly, Sandipta Roy, Mainak Mukhopadhyay

58. Role of Sodium–Glucose Transport Protein 2 Inhibitors in Septic Cardiomyopathy **343**
Gaurav Kochhar, Yatin Mehta

59. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Takotsubo Syndrome-inflicted Cardiomyopathy **347**
Sarita Gulati, Chaitanya Gulati

60. Sodium–Glucose Cotransporter 2 Inhibitors in Rheumatic Heart Disease with Heart Failure **355**
Arati Dave Lalchandani

61. Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Fighting the Enemy with a Newly Crafted Weapon **357**
Harshit Khare, Aditya Kapoor

62. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Atrial Fibrillation **360**
Shraddha Ranjan, Kartikeya Bhargava

63. Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Atrial Fibrillation with Stroke, Peripheral Vascular Disease **364**
NN Khanna, Sushant Mishra, Swati Singh

64. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Stroke and Atrial Fibrillation in Diabetes Mellitus **369**
Vitull K Gupta, Preeti Singh Dhoat, Meghna Gupta, Varun Gupta

65. Sodium–Glucose Cotransporter 2 Inhibitors (A Tale of Salt, Sugar, and Cancer): Mortality and Morbidity Benefits in Heart Failure with Cancer **373**
Indu Bansal Aggarwal, Hemant Madan, Harmesh Aggarwal

66. Role of Impella in Patients with Shock and Heart Failure **379**
Sarita Rao, Roshan Rao, Kamlesh Kothawade, Achukatla Kumar

67. Dapagliflozin in Heart Failure with Preserved Ejection Fraction **386**
Mohit Jindal, Ankit Tandon, Rohit Tandon

68. Role of Sodium–Glucose Cotransporter 2 Inhibitor in All Spectrums of Heart Failure **389**
Dev Pahlajani, Pradeep Hasija

69. Mortality and Morbidity Benefits of Sodium–Glucose Cotransporter 2 Inhibitors **397**
Sunil Modi, Ranjan Modi

70. Sodium–Glucose Cotransporter 2 Inhibitors in Worsening Heart Failure **401**
AK Pancholia

71. Sodium–Glucose Cotransporter 2 Inhibitor in Heart Failure with Diabetes and Chronic Kidney Disease **407**
Sarita Bajaj, Yashaswi Pathak, Lekharaj Choudhary

72. Sodium–Glucose Cotransporter 2 Inhibitors in Chronic Kidney Disease and Congestive Cardiac Failure **411**
Sunil Prakash, Prabin K Majhi

73. Left Atrial Failure: The Role of SGLT2is, ARNI, Bisoprolol, and MRAs **418**
Harinder K Bali, Navdeep S Sidhu

74. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and Mortality in Diabetes Mellitus **424**
Namrata Gaur, Dushyant Singh Gaur

75. Cardiovascular Outcome Trials with Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes **431**
Rajeev Chawla, Shalini Jaggi, Siddhant Trehan

76. Development of Treatment Selection Algorithm for Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure **436**
Devesh Kumar, Nirmal Ghati

77. Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cardiac Remodeling: Beyond Glycemic Control **440**
Chandrashekhar K Ponde, Mohit Singhal

78. Vascular Remodeling Reversal and Improvement of Endothelial Dysfunction by Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure **444**
Shishu Shankar Mishra, Biswaranjan Mishra

79. Dipeptidyl Peptidase 4 Inhibitors and Cardiovascular Outcome [Heart Failure (HF)]: From Bench to Bedside **450**
HK Chopra, Chandrashekhar K Ponde, AK Pancholia, Jignesh Ved

Beta-blockers in Heart Failure

80. Bisoprolol Outcome Data in Hypertension to Heart Failure **456**
Deepa Malik, JPS Sawhney, Ayush Kumar

81. American College of Cardiology/American Heart Association Guidelines on Beta-blocker Use in Heart Failure **463**
Vineet Bhatia, Meetu Arora, Upendra Kaul

82. Promise of Bisoprolol in Heart Failure: Present Status **467**
Ajay Kumar Sinha, Shraddha Ranjan, Sushil Kumar, Pawan Kumar Singh, Shreyash Trived, Deepashree, Manish Singh

83. Bisoprolol in Resistant Hypertension with Heart Failure: A Rising Star and not an Illusion **474**
HK Chopra, Anu Grover, AK Pancholia, Anil Pareek

84. Uniqueness of Bisoprolol in Heart Failure **482**
HK Chopra, Chandrashekhar K Ponde, Anu Grover, NR Shastry

85. Role of Bisoprolol in Chronic Kidney Disease with Heart Failure **491**
Himanshu Verma, Sourabh Sharma

86. Role of Bisoprolol in Heart Failure with Stroke and Hypertension **498**
Pradeep Jain, Deeptanshu Jain, SN Pathak

87. Uniqueness of Beta Blockers in Heart Failure **501**
Komal Dahiya, Rajiv Passey

88. Morbidity and Mortality Benefits of Bisoprolol in Heart Failure **506**
Dhiman Kahali, Asit Das, Sreya Mazumder

89. Role of Bisoprolol in Heart Failure with Diabetes Mellitus **514**
Vinod Mittal

90. Role of Bisoprolol in Severe Mitral Regurgitation and Heart Failure **518**
SB Gupta

91. Bisoprolol in Hypertension to Heart Failure **523**
SN Narasingan, Aravind Duruvasal

92. Role of Bisoprolol's Survival Benefits in Heart Failure **528**
Ameet G Sattur

93. Bisoprolol in Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction **532**
Rohit Walia, Mohit Walia, Deepanshu Dhiman

94. Role of Bisoprolol in Tachyarrhythmia with Heart Failure **536**
Jostol Pinto, A George Koshy

95. Role of Bisoprolol in Heart Failure Postmyocardial Infarction **540**
Purneshwar Kumar Pandey, Mitendra Singh Yadav

96. Bisoprolol in Heart Failure due to COVID, Septic, and Peripartum Cardiomyopathy **545**
Meera R, Vijayaraghavan G

97. The Role of Bisoprolol in Primary, Secondary, and Tertiary Prevention of Sudden Cardiac Death in Heart Failure **550**
Kiron Varghese

98. Reverse Cardiac Remodeling: Role of Beta-blockers **554**
Chandrashekhar K Ponde, Kunal A Patankar

99. Beta Blockers in the Management of Chronic Heart Failure **558**
M Somasundaram, GV Senthilnathan, R Divya

100. Use of Beta-blockers in Patients with Heart Failure and Comorbidities **562**
I Sathyamurthy, KN Srinivasan

101. Beyond Beats: Deciphering Bisoprolol in Heart Failure Care **566**
Tiny Nair, HK Chopra, Sanjay Jain, Onkar C Swami

Ferric Carboxymaltose and Heart Failure

102. Ferric Carboxymaltose: A Fifth Pillar in Heart Failure Management **575**
Aniruddha De

103. European Society of Cardiology Recommendation for Ferric Carboxymaltose in Heart Failure **582**
Satyanarayan Routray, Nirmal Kumar Mohanty, Siddhartha Pandey

104. Ferric Carboxymaltose in Heart Failure with Kidney Disease 585
Dilip Bhalla, Ramesh Kumar Sah, Retesh Kumar Singh

105. Global Data on Ferric Carboxymaltose in Heart Failure 590
Prabhakar Dorairaj, Adhiti Krishnamoorthy

106. Iron Deficiency and Heart Failure: Current Perspective 595
Saumitra Ray, Srina Ray

107. Navigating Heart Failure: Unraveling the Role of Ferric Carboxymaltose in Comprehensive Patient Care 599
HK Chopra, Heena Bhojwani, Sanjay Jain, Onkar C Swami

Mineralocorticoid Receptor Antagonists and Heart Failure

108. Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction 610
VV Muthusamy, Dhanvanth Rajesh B, Anand Priya VVM, LN Meena

109. Mineralocorticoid Receptor Antagonists in HFrEF: ACC/AHA Guidelines 615
Abhishek, Nikita Sharma, Gurpreet Singh Wander

110. Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: Outcome Data 620
Rajan Joseph Manjuran

Vericiguat and Heart Failure

111. Vericiguat in Heart Failure: What are the Guidelines? 622
SS Iyengar, Sneha Karekar

112. Vericiguat in Heart Failure 627
J Cecily Mary Majella, Geetha Subramanian, Surendran

113. Vericiguat in Heart Failure: Scientific Evidence to Clinical Practice 631
Vishal Rastogi, Pragya Kumari, Vijay Kumar

114. Worsening Heart Failure: Identifying the Patient Who will Benefit with Vericiguat 638
Vidyut Jain, Avani Jain

SECTION 3: DIAGNOSTIC BIOMARKERS

115. Role of N-terminal Fragment of pro-B-type Natriuretic Peptide: Diagnostic, Prognostic, and Therapeutic Implications 647
Srikanta Sharma, Aayushi Gupta, Lalatendu Mohanty, HK Chopra

SECTION 4: ECHO, IMAGING AND HEART FAILURE

116. Effect of Angiotensin Receptor–Neprilysin Inhibitors on Left Ventricular and Left Atrial Strain in Heart Failure 655
Donovon Allen, Srijani Thannir, Navin C Nanda, HK Chopra

117. Echocardiographic Reverse Remodeling with Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure 660
Shivani Priyadarshni, Aiham Albaeni, Masood Ahmad

118. Echocardiographic-guided Therapy in Heart Failure 665
Dennis Fong, Iniya Rajendran, Rajesh Janardhanan

119. Effect of E/e' in Heart Failure Patients on Angiotensin Receptor–Neprilysin Inhibitor Therapy **674**
Naveen Garg, KK Kapur

120. Impact of Sodium–Glucose Cotransporter 2 Inhibitor on E/e' in Patients with Heart Failure **680**
Naveen Garg, KK Kapur

121. Echocardiographic Assessment of Left Ventricular Hypertrophy and Left Atrial Volume in Heart Failure **685**
Manish Bansal, Ravi R Kasliwal, HK Chopra, Karishma Walia

122. Echocardiographic Evaluation of Heart Failure in Emergency **694**
Rekha Mishra, Uday S Yadav, Amitabh Poonia

123. Echocardiography Evaluation of the Left Atrial Strain on Patients with SGLT2 Inhibitors with Heart Failure **707**
Amrish Agrawal, Thair Al Jumaily, Vishal Agrawal, Tarik Salim

124. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Increased Left Atrial Stiffness Index in Heart Failure **712**
Pritam Kitey, Mohit Bhagwati, Rahul Mehrotra, Amitabh Yaduvanshi, Vikas Kataria, Shivank Gupta

125. Heart Failure in Hypertrophic Cardiomyopathy Mechanisms and Management **718**
S Shanmugasundaram, U Ilayaraja, BG Vinodkumar

126. Echocardiographic Variables on Cardiac Remodeling Reversal by Bisoprolol in Heart Failure **734**
Ankush Sachdeva, Sanil Omar, Ashok Kumar Omar

127. Echocardiographic Evaluation of Right Ventricular Parameters in Heart Failure—On ARNI and SGLT2i **739**
Satish C Govind

128. Cardiac Magnetic Resonance Imaging Evaluation on Cardiac Remodeling Reversal after Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure **745**
Priya Jagia, Damandeep Singh

129. Cardiac Magnetic Resonance Evaluation on Cardiac Remodeling Reversal after Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure **753**
Mona Bhatia, Parveen Kumar, Prasit Maity, Amit Garg, Karthika Gopal, Sachin Raiya, Akash

130. Role of Computed Tomography Evaluation for Transcatheter Aortic Valve Implantation **757**
Anshika Gulati, Parveen Gulati

131. Angiotensin Receptor–Neprilysin Inhibitor and Extracorporeal Membrane Oxygenation **763**
Poonam Malhotra Kapoor

132. Sodium–Glucose Cotransporter 2 Inhibitor and Extracorporeal Membrane Oxygenation in Heart Failure **770**
Poonam Malhotra Kapoor

SECTION 5: CARDIAC RESYNCHRONIZATION THERAPY AND DEVICE

133. Does Angiotensin Receptor–Neprilysin Inhibitor Postpone the Need of Device Therapy in Heart Failure with Reduced Ejection Fraction? **779**
Viveka Kumar

SECTION 6: CORONARY ARTERY DISEASE AND HEART FAILURE

134. Acute Coronary Syndromes and Heart Failure **783**
Brian Pinto, Bhavik Dhirawani, Neeraj A Desai

135. Role of Sodium–Glucose Cotransporter 2 Inhibitors Post-CABG with Heart Failure **789**
Anirban Kundu, OP Yadava

SECTION 7: STROKE AND HEART FAILURE

136. Sodium–Glucose Cotransporter 2 Inhibitors in Stroke Prevention **797**
Vinit Suri, Kunal Suri, Kanika Suri

137. Role of Angiotensin Receptor–Neprilysin Inhibitors in Stroke **803**
Vaibhav Deorari, Mukesh Kumar, Nilesh Jadhao, Joy Dev Mukherji

SECTION 8: ARRHYTHMIA AND HEART FAILURE

138. Newer Left Ventricular Assist Devices: Current Scenario **811**
G Justin Paul, J Cecily Mary Majella

139. Review Outcomes of Recent Device Trials in Heart Failure **820**
Aparna Jaswal, Wasim Rashid

SECTION 9: HYPERTENSION

140. Hypertension and Heart Failure as Stroke Risk Factors **827**
Pawan K Sharma, HK Chopra

141. Heart Failure and Hypertension **833**
Jostol Pinto, A George Koshy

SECTION 10: VALVULAR

142. Heart Support Devices in Heart Failure **841**
Vivudh Pratap Singh, Vishal Rastogi, Vijay Kumar, Ashok Seth

SECTION 11: CONGENITAL HEART DISEASE AND HEART FAILURE

143. Heart Failure in Pediatric Group **853**
Hala Elmarsafawy, Shimaa Khaled

144. End-stage Congestive Heart Failure between the Present and the Future: Is there a Pharmaceutical way to get around it? **865**
Sonia El Saeidi, Antoine Abdel Massih

145. Sodium–Glucose Cotransporter 2 Inhibitors in Pediatric Heart Failure: A Promising Adjuvant/Guidelines **868**
IB Vijayalakshmi, Akkatai S Teli

SECTION 12: NUTRITIONAL

146. Coenzyme Q10 Deficiency and Heart Failure **873**
Pawan K Sharma, HK Chopra

147. Evolving Scenario of Edible Oils in India: A Scientific Perspective on their Prospective Role in the Management of Noncommunicable Diseases **879**
Shashank Joshi, Shilpa Vora

SECTION 13: HEART FAILURE AND CARDIO-ONCOLOGY

148. Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure with Cancer Patients **891**
Kanika Sharma Sood, Mohit Rana, Aditi Tanwar

149. Echocardiography Evaluation of Heart Failure in Oncology **894**
Madhu Mary Minz, Manish Bansal, Ravi R Kasliwal, HK Chopra

SECTION 14: REHABILITATION

150. Exercise Protocol in HFrEF on ARNI, SGLT2i, MRA, and Bisoprolol **907**
Chetan P Shah, Charan Reddy KV

151. Role of Yoga in Heart Failure **912**
SC Manchanda, Ashish Kumar Jain, Kushal Madan

SECTION 15: ARTIFICIAL INTELLIGENCE

152. Artificial Intelligence: Its Impact in the Management of Heart Failure **919**
Vidur Mahajan, Vasanthakumar Venugopal

Index *925*